BioFuels Journal

Jupiter, Fla., April 28, 2015 — Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company with patented and proprietary technologies used to develop and produce enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceuticals, and industrial enzymes industries, today announced the receipt of $800,000 for achieving two additional research and development milestones in its funded research program with BASF, a Dyadic C1 Technology licensee.

"We are excited to have met these milestones as a result of our funded research project with BASF.

"Dyadic's C1 technology continues to achieve new heights of performance and application potential.

"The program objectives were accomplished ahead of schedule, with a purer enzyme profile and higher productivity levels than those expected at the beginning of the BASF project.

"These achievements continue to demonstrate the power of applying our C1 expression technology in the development of enzyme and other protein products from a virtually unlimited number of genes being discovered at an accelerated pace due to the plummeting costs of gene sequencing.

"C1-based products can be manufactured in very large quantities, with greater purity, resulting in more specific performance and increased profitability.

"This next-generation 'White Strain 2.0,' represents the culmination of over twenty years of research and development of our patented C1 organism, Myceliopthora thermophila," said Mark Emalfarb, founder & CEO of Dyadic International Inc.

Dr. Wim van der Wilden, General Manager of Dyadic's research laboratory in the Netherlands, added, "The investment made in the expansion of laboratory and scientific staff over the last 18 months has contributed to these and other scientific advances.

"The successful completion of these additional scientific milestones further highlights our strengths for turning DNA into commercial products and the vast and unlimited potential for doing so.

"We are thankful to have world-class partners like BASF using Dyadic's C1 technology and are very proud of these scientific and commercial accomplishments."

Under the terms of our license agreement with BASF, Dyadic will receive royalty payments based on the revenue from products sold using our C1 technology.

For more information, please contact Thomas L. Dubinski at 561-743-8333 or tdubinski@dyadic.com

See Related Websites/Articles:

• Dyadic International

more ADVANCED BIOFUELS...